School of Chinese Medicine
Drug delivery nanocarriers, especially targeted drug delivery by liposomes are emerging as a class of therapeutics for cancer. Early research results suggest that liposomal therapeutics enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumors and active cellular uptake. Here, we highlight the features of immunoliposomes that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While a large number of studies has been published, the emphasis here is placed on the carbonic anhydrase IX (CA-IX) and the conjugated liposomes that are likely to open a new chapter on drug delivery system by using immunoliposomes to deliver anticancer ingredients to cancer cells in vivo.
Anticancer ingredients, Cancer cell penetrating peptides, Carbonic anhydronase IX (CA-IX), Immunoliposomes, In vivo delivery
Source Publication Title
International Journal of Molecular Sciences
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Hong Kong Baptist University Research Grant support and the University Grants Committee of Hong Kong General Research Fund (GRF)
Link to Publisher's Edition
Helena Ng, Huei Leng, Aiping Lu, Ge Lin, Ling Qin, and Zhijun Yang. "The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo." International Journal of Molecular Sciences 16.1 (2014): 230-255.